Get started
Breaking: Vision Marine Technologies (VMAR) Set For 1700% SurgeVision Marine Technologies Inc. (NASDAQ: VMAR) is set poised to capitalied on a patterned from on the 12 hour price chart pattern called the U-shaped cup shape which is a bullish pattern depending on the trend and shape of the cup. With the Relative Strength Index (RSI) at 29, NASDAQ:VMAR is looking poised to capitalized on this dip that is forming a U-shaped cup pattern looking forward to delivering a 1700% surge. As of the time of writing, the stock closed Monday's session up by 9.07% showing an increased in the influx of buyers. About VMAR Vision Marine Technologies Inc. designs, develops, manufactures, rents, and sells electric boats in Canada, the United States, and internationally. The company offers e-motion electric powertrain technology; e-motion electric outboard powertrain system; electric boats; and maintenance, repair, and customer support services, as well as manufactures customized boats. Financial Performance In 2024, VMAR's revenue was 3.79 million, a decrease of -32.86% compared to the previous year's 5.65 million. Losses were -14.06 million, -32.65% less than in 2023. Analyst Forecast According to Lucas Ward from Ascendiant Capital, the rating for VMAR stock is "Strong Buy" and the 12-month stock price forecast is $270.0 with a whopping +5,057.10% returns
NASDAQ:VMARLong
by DEXWireNews
Moderna (MRNA) Shares Plunge Nearly 9%Moderna (MRNA) Shares Plunge Nearly 9% Moderna (MRNA) shares tumbled by approximately 8.9%, falling below $29—marking their lowest level since April 2020, when global markets were shaken by the COVID-19 pandemic. Since the start of 2025, MRNA’s share price has declined by around 32%. Why Did MRNA Shares Drop? On Monday, MRNA led the decline among US biotech stocks following the resignation of Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research. Marks had held this position for over a decade. During Trump’s first term, Marks oversaw the rollout of COVID-19 vaccines and established guidelines for emerging treatments such as cell and gene therapy. However, in Trump’s second term, Robert F. Kennedy Jr. now serves as Health Secretary. According to The Wall Street Journal, Marks criticised Kennedy’s stance on vaccines in his resignation letter, calling it “misinformation and lies.” The pharmaceutical industry was already under pressure amid speculation that Trump’s tariff plans could extend to prescription drugs, which are typically exempt from such measures. Marks' departure has further intensified uncertainty regarding regulatory decisions under the new administration. Technical Analysis of MRNA Shares The chart indicates that: ➝ The stock remains in a downtrend that began with a sharp drop in August last year (reinforced by the moving average). ➝ Over the past five months, it has been forming a descending channel (marked in red). ➝ The lower boundary of this channel acted as support yesterday. The formation of higher lows and highs (marked in blue) had given bulls some hope in March 2025. However, yesterday’s bearish gap appears to have shattered that optimism. It is possible that the lower blue trendline and the median of the red channel will act as resistance moving forward, further darkening the outlook for MRNA’s share price—especially given the ongoing negative news surrounding the stock. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NASDAQ:MRNA
by FXOpen
1
$NIO Wyckoff Accumulation – Schematic #1 or #2 in PlayMy base case at the moment is Wyckoff Accumulation Schematic #2 , where the Secondary Test ( ST-B ) could mark the very bottom. This idea will be validated for me especially if we see interaction with the High Time Frame Channel projection. Green Zone: We have multiple levels of confluence around this zone: 0.786 Fibonacci Retracement from the 2020 low to the 2021 top MO – Monthly Open level Volume cluster from previous local consolidation Blue Zone: If price drops as low as VAL, I expect it to be just a quick, volatile wick breaching into the Blue Zone. High Time Frame Channel projection:
NYSE:NIOLong
by Bulltro
2
Cracks Appearing in J&J's Armor?Johnson & Johnson, a long-established leader in the global healthcare sector, confronts substantial challenges that raise significant questions about its future trajectory and stock valuation. Foremost among these is the persistent and massive litigation surrounding its talc-based baby powder. With tens of thousands of lawsuits alleging links to cancer, the company's strategy to manage this liability via bankruptcy has been repeatedly struck down by courts, most recently rejecting a $10 billion settlement proposal. This forces J&J to potentially face over 60,000 individual claims in court, introducing immense financial uncertainty and the prospect of staggering legal costs and damages. Compounding these concerns is mounting scrutiny over the company's historical and recent marketing practices. A federal judge recently imposed a $1.64 billion penalty against J&J's pharmaceutical arm for misleading marketing of HIV medications, citing a "deliberate and calculated scheme." This follows earlier multi-million dollar settlements related to alleged improper financial inducements paid to surgeons for orthopaedic implants by its DePuy subsidiary, and tax disputes in India over questionable "professional sponsorship" expenses tied to similar activities. These incidents depict recurring legal and ethical entanglements with significant financial penalties and reputational harm. Taken together, the unresolved talc litigation, substantial financial penalties from marketing violations, and persistent questions regarding ethical conduct create considerable headwinds for Johnson & Johnson. The cumulative impact of ongoing legal battles, potential future liabilities, and damage to its corporate image threatens to drain resources, divert management focus from core operations, and erode investor confidence. These converging factors present tangible risks that could exert significant downward pressure on the company's stock price moving forward.
NYSE:JNJShort
by UDIS_View
$RIOT / 3hEventually All Waves Settle!! The market selloff in five straight trading days has extended the current decline in wave(c) and exceeded the last extreme low at 7.24 as well. It would suggest the ending contracting diagonal in wave (c) to morph into an expanding diagonal, as adjusted on this frame. So, NASDAQ:RIOT may have concluded the entire correction in Minor degree wave 2 by an ending expanding diagonal in its wave (c) of ((y)) on the Fib 1.618 expansion level(very close to 6.87). The Redline >> 6.36 #CryptoStocks #RIOT #BTCMining #Bitcoin #BTC
NASDAQ:RIOT
by ElliottChart
SAR Be the Next MEME Stock?Chart Outlook: Bullish Structure on 12M Key Resistance: $40.50 Current Price: ~$25.20 Dividend Yield: 11.79% 😳 Speculation meets fundamentals. SAR is not your typical meme stock candidate. It’s a high-yielding, income-generating BDC (Business Development Company) with solid fundamentals, strong net margins, and steady dividend payouts. But lately… the internet’s been talking 👀 🚀 Meme Fuel? Viral images and tweets of Saratoga water are starting to circulate. The name “Saratoga” is catching on thanks to the crossover between the Primo Brands hype and fitness culture. Social sentiment is up, and chatter is growing louder in meme stock circles. 🧾 Fundamentals Still Matter: Steady upward trend from all-time lows around $6. Key level at $40.50 remains a major psychological and technical resistance. Payout ratio is high (~118%), meaning dividends may be pressuring earnings—but the yield is very attractive to long-term holders. 📈 Technical Perspective: 12-month chart shows a clear uptrend off the bottom. Accumulation appears to be happening just under resistance, forming higher lows. A breakout above $26.50 could set the stage for a momentum move toward $30+. 🎯 Conclusion While SAR isn’t a meme stock by definition, the perfect storm of meme potential + real fundamentals could push it into the spotlight. Volume will be key—watch for a surge in retail interest and a break above previous highs. Will SAR go viral next? Or is this a slow climb for patient income investors? Either way… eyes on $40.50. 🧠 This is not financial advice. Just sharing what I see in the charts—do your own research before entering any position. #SAR #DividendStocks #MemeStocks #BDC #TechnicalAnalysis #Robinhood
NYSE:SARLong
by MoNi_MoN
ASML is on life support Warning: This baby is super volatile and not for beginners. If you’re trading with a small account, start with 1 share and put your stop in as soon as you enter. No exceptions. We’ve got 3 lower highs, and there are institutional sellers parked near the 200-day EMA, slowly walking this thing down. If they press, I’m watching to see if ASML can test the $650 area. If it breaks, we might be looking at another 50–60 points lower. 📌 Tight stop: $750 📌 Wider stop: $770 This one isn’t for the faint of heart—respect the volatility and use stops!
NASDAQ:ASMLShort
by onlytrade2win